rs117504035 - ITPRIPL2-AS1 - SYT17

Magnitude 4.5 · 1 study on file

Reported associations

• Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study. - Endocrine-related cancer (2023) · Shiota M, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, Kamba T, Fujimoto N, Sekine Y, Kimura H, Narita S, Terada N, Momozawa Y, Akamatsu S, Habuchi T, Yokomizo A, Naito S, Eto M · PubMed 37079309

  Androgen-deprivation therapy (ADT) has been widely used for the treatment of advanced prostate cancer. However, prognosis and adverse events (AEs) vary among patients. This study aimed to identify genetic markers able to predict the outcome of ADT. Japanese patients treated with primary ADT for advanced prostate cancer in the KYUCOG-1401 trial were enrolled as a development set. A distinct population of advanced prostate cancer cases treated with ADT was included as a validation set. Single-nucleotide polymorphisms (SNPs) associated with radiographic progression-free survival (rPFS) at 1 year and AEs including de novo diabetes mellitus (DM), arthralgia, and de novo dyslipidemia were identified in the development set by a genome-wide association study (GWAS). The SNPs associated with rPFS i

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.